217 related articles for article (PubMed ID: 11458523)
1. Dendritic cell-based vaccines in patients with hematological malignancies.
Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
[TBL] [Abstract][Full Text] [Related]
2. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope.
Andersen RS; Wenandy L; Sørensen RB; thor Straten P; Andersen MH
Leukemia; 2008 Mar; 22(3):668-9. PubMed ID: 17805325
[No Abstract] [Full Text] [Related]
4. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
5. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
8. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
9. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
[TBL] [Abstract][Full Text] [Related]
10. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
11. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
[TBL] [Abstract][Full Text] [Related]
12. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
13. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
14. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
15. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Takaki T; Hiraki A; Uenaka A; Gomi S; Itoh K; Udono H; Shibuya A; Tsuji T; Sekiguchi S; Nakayama E
Int J Oncol; 1998 May; 12(5):1103-9. PubMed ID: 9538136
[TBL] [Abstract][Full Text] [Related]
16. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
[TBL] [Abstract][Full Text] [Related]
17. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
18. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
19. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
Brossart P; Wirths S; Stuhler G; Reichardt VL; Kanz L; Brugger W
Blood; 2000 Nov; 96(9):3102-8. PubMed ID: 11049990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]